Cyclic peptide nanocarriers overcome drug resistance and improve targeted colon cancer treatment | Research

The takeaway

Cyclic peptide-based nanocarriers (liposomes, niosomes, nanosponges) improve drug delivery, tumor penetration, and drug resistance in colon cancer by combining cyclic peptide anticancer activity with nanocarrier controlled release.

Overcome drug resistance
Cyclic peptide nanocarriers combine natural anticancer activity with targeted delivery to address colon cancer drug resistance—a key clinical challenge

What the researchers found

Cyclic peptides: structural stability, enhanced bioavailability, target specificity. Nanocarrier types: liposomes, niosomes, nanosponges, nanopolymers. Benefits: targeted delivery, controlled release, drug resistance overcome. Sources: plant, marine, microbial.

Why it matters

Colon cancer is a leading cause of cancer death, and drug resistance limits treatment. Cyclic peptide nanocarriers address both challenges: natural anticancer activity plus smart delivery to overcome resistance.

How the study worked

Comprehensive narrative review of cyclic peptide sources, mechanisms, therapeutic applications, and nanocarrier integration for colon cancer.

What this study cannot tell us

Review of primarily preclinical data. Clinical translation of cyclic peptide nanocarriers is early. Manufacturing complexity and cost unknown. In vivo efficacy data limited.

How to read the evidence

Narrative review of preclinical advances. Promising technology platform but limited clinical data.

When this study was published

Published in 2025.

The bigger picture

Cyclic peptides bridge natural products and nanotechnology, combining evolution-refined anticancer activity with engineered delivery precision for one of the most common and deadly cancers.

Questions still open

Which cyclic peptide nanocarrier is closest to clinical trials?
Can these systems be adapted for other GI cancers?
How do cyclic peptide nanocarriers compare to antibody-drug conjugates?

Common questions

What are cyclic peptides?

Cyclic peptides are small proteins that form a ring structure, making them more stable than linear peptides. Many found in nature (from plants, sea creatures, and microbes) have powerful anticancer properties. Their ring shape also makes them better at entering cells and resisting breakdown in the body.

How do nanocarriers improve colon cancer treatment?

Nanocarriers are tiny particles that protect drugs during transport through the body and release them specifically at the tumor site. By attaching cyclic peptides to nanocarriers, researchers achieve double benefit: the nanocarrier delivers the drug precisely to the colon tumor, while the cyclic peptide provides its own anticancer effect and helps overcome drug resistance.

Read the original research

Unlocking the Therapeutic Potential of Cyclic Peptide-Based Nanocarriers for Enhanced Colon Cancer Treatment.

The protein journal, 44(6), 691-716

View on PubMed ↗Publisher’s paper ↗

Citation

Souresh, Vedhapriya; Srikayalsamyukktha, M; Harini, M; Saravanan, Yudhesh; Saravanakumar, Rupachandra. (2025). Unlocking the Therapeutic Potential of Cyclic Peptide-Based Nanocarriers for Enhanced Colon Cancer Treatment.. The protein journal, 44(6), 691-716. https://doi.org/10.1007/s10930-025-10289-2